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Dear Editor,
Rowell’s syndrome is a rare disease, characterized 
by the appearance of erythema multiforme (EM)-like 
lesions in patients with lupus erythematosus. It was 
initially reported by Rowell (1) in 1963 and its exis-
tence as a separate clinical entity is currently under 
debate (2,3). A few cases may have been induced by 
drugs such as systemic antimycotics, antibiotics, anti-
convulsants, and more recently proton pump inhibi-
tors (PPIs). 
CASE REPORT
We present the case of a 67-year-old woman with 
subacute cutaneous lupus erythematosus (SCLE) and 
EM-like lesions who fulfilled all the criteria for Row-
ell’s syndrome. The patient had lupus arthritis for two 
years and was treated with oral methylprednisolone 
8 mg/day and hydroxychloroquine 200 mg/day. She 
started receiving 20 mg of omeprazole daily for gas-
troprotection. The patient also had arterial hyperten-
sion with no current treatment, osteoporosis, and an 
L1 vertebral fracture.
The dermatological examination revealed multi-
ple erythematous infiltrated plaques involving main-
ly the sun-exposed areas (neck, chest, upper back, 
and shoulders). Cutaneous lesions had an annular or 
target pattern and a tendency to form hemorrhagic 
crusts and scales at the margins (Figure 1, A). The mu-
cous membranes were unaffected.
Histological examination (hematoxylin and eosin 
×200) found epidermal atrophy, vacuolar degenera-
tion of the basal layer, and sparse perivascular lym-
phocytic infiltrate in the dermis – features corre-
sponding to lupus erythematosus (Figure 2, A). Single 
eosinophilic necrotic keratinocytes characteristic for 
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erythema multiforme were observed in the epider-
mis (Figure 2, B). Direct immunofluorescence (IF) from 
lesional skin showed granular deposits of C3 on the 
dermo-epidermal junction. Lupus band test from sun-
protected, nonlesional skin was negative. On indirect 
IF a speckled pattern antinuclear antibodies (ANA) 
with >1:1280 titers were detected. Anti-Ro (>200 U/
mL) and anti-La (>200 U/mL) antibodies were also 
positive. The blood cell count and differential analysis 
were within reference ranges. The 24-hour urine pro-
tein test showed a non-significant proteinuria – 0.36 
g/24h. Photo-testing was impossible considering the 
extent of the skin lesions. 
The therapeutic approach consisted of increasing 
the hydroxychloroquine dose to 400 mg/day, substi-
tuting PPI with famotidine 20 mg/day p.o. and ceftri-
axone 2 g/day for the superinfection with Ps. aerugi-
nosa, which led to a clinical improvement (Figure 1, B). 
The methylprednisolone dose remained unchanged 
due to already existing severe adverse effects.
DISCUSSION
The diagnosis was based on Zeitouni et al.’s clas-
sification (4). The three main criteria are as follows: 
lupus erythematosus, EM-like lesions, and speckled 
pattern of ANA. Our patient met all three major and 
one minor criteria, namely the presence of anti-Ro 
and anti-La antibodies. As for the other minor criteria, 
RF was negative and no chilblains were found. 
Although there was a continuous time lapse (more 
than 1 year) between the initiation of omeprazole in-
take and the diagnosis of Rowell’s syndrome, we sug-
gest that the connection is probable. For instance, 
the latency differs depending on the incriminated 
medication in drug induced SCLE. Longer periods are 
reported for diuretics and calcium blockers, while the 
time interval is shorter for chemotherapeutic drugs 
and antimycotics (5). Our suspicions were further con-
firmed by the fact that the lesions improved promptly 
within a month after discontinuation of omeprazole 
and doubling the dose of hydroxychloroquine.
PPIs are reported to be a major cause of drug-in-
duced SCLE (6,7). According to Laurinaviciene et al., 
the most common drugs involved are PPIs, thiazide 
diuretics, antifungals, chemotherapeutics, statins, 
and antiepileptics (6). However, very few cases of 
Rowell’s syndrome are found to be drug-related. The 
culprit drugs include: oral terbinafine (8,9), norfloxa-
cin (10), sodium valproate (11) and esomeprazole (12) 
(Table 1).
CONClUSION
Despite the common clinical and immunological 
features shared between SCLE, drug-induced SCLE 
and EM, Rowell’s syndrome seems to be a separate 
entity rather than a coincidental association. Finally, 
according to our knowledge this case would be the 
second of Rowell’s syndrome due to PPIs.
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Fig. 1 (a) Multiple erythematous infiltrated plaques affecting 
the back with annular and target character and a tendency 
to form haemorrhagic crusts and scales at the margins; (b) 
The improvement of skin lesions after 4 weeks treatment
Fig. 2 (a) Skin biopsy revealing epidermal atrophy, vacuolar 
degeneration of the basal layer, sparse perivascular 
lymphohistiocytic infiltrate in the dermis - features 
corresponding to lupus erythematosus (hematoxylin and 
eosin x200); (b) Single eosinophilic necrotic keratinocytes 
in the epidermis, characteristic for erythema multiforme 
(hematoxylin and eosin x200).
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